Single Cell Multi-Omics Market Growth, Drivers, and Opportunities

Single Cell Multi-Omics Market - Global Forecast 2029

Report Code: UC-HC-6825 Feb, 2026, by marketsandmarkets.com

The global single cell multi-omics market, valued at US$XX billion in 2023, is forecasted to grow at a robust CAGR of XX%, reaching US$XX billion in 2024 and an impressive US$XX billion by 2029. The major factors driving the growth of this market are technological advancements in the sequencing technology and multi-omics analysis. Significant developments have been made in the arena of single cell multi-omics in the past few years. For instance, simultaneous detection of chromatin accessibility and transcriptome in a single cell sample provides a direct link between chromatin state and the level of the corresponding transcripts. Such technological advancements are set to propel the market growth.

SINGLE CELL MULTI-OMICS MARKET- GLOBAL FORECAST TO 2029

Single Cell Multi-Omics Market

GLOBAL SINGLE CELL MULTI-OMICS MARKET DYNAMICS

Driver : Rising technological advancements in multi-omics

Increasing advancements in multi-omics, particularly in the realm of sequencing is set to drive the market growth. Advancement's in NGS and new chemical library-screening approaches have enabled mapping of genome-wide interactions between small molecules with chromatin could provide new insights into the mechanisms. Emerging technologies have focused on enabling the detection of the drug-DNA interaction in the past few years. For instance, Chem-seq technology makes use of affinity tags reacting with the functionalized drugs, which further make it possible to identify global interactions of small molecules in bulk samples. Single cell multi-omics offers a multi-molecular readout which helps in comprehensive dissection of complex molecular mechanisms in gene regulation, depicting individual cell states to utmost accuracy. These technologies are well-suited for end-uses involving rare cell types, as it maximizes the information obtained from each individual cell. Such approaches have immense potential applications in a wide range of research fields, from developmental biology to cancer biology and precision medicine related to drug research and development.

Challenge : Complexities associated with data analysis

Single cell multi-omics is a complex technology, which yields an array of datasets based on the analysis of genome, proteome, and transcriptome – all in one sample. Joint analyses of data is challenges with both the cross-modality variations and cross-cell correlations. The challenges in developing such integrative methods for scMulti-omics data include unifying different modalities, batch effects between experiments (especially for unmatched data), low sequencing depth, and high-modality interactions. Recently emerged methods for integrating single cell multi-omics data provide new opportunities to jointly analyze different types of single-cell data, there remain several challenges and issues to address for the future of scMulti-omics studies and integrative methods. One challenge is related to the computational issues in dealing with large data. Analyzing massive amounts of data from technologies such as RNA-seq, whole-genome sequencing, and ChIP-seq is an established problem due to their sheer size. Furthermore, single-cell methods have the computational burden of including information from hundreds or thousands of cells.

Key Market Players

OXFORD NANOPORE TECHNOLOGIES PLC.
ILLUMINA, INC.
BD
MERCK KGAA
AGILENT TECHNOLOGIES, INC.
THERMO FISHER SCIENTIFIC
BRUKER
DANAHER CORPORATION
QIAGEN
PACBIO
BIO-TECHNE
STANDARD BIOTOOLS
BIO-RAD LABORATORIES, INC .

Recent Developments:

In January 2025, Illumina, Inc. a global leader in DNA sequencing and array-based technologies, today announced a series of updates to its NovaSeq X Series, delivering the NovaSeq X single-flow-cell system alongside a cutting-edge software upgrade and new kits.
In July 2024, MedGenome, a leading provider of multiomics solutions, today announced the acquisition of a PacBio Revio sequencing system. This latest addition to MedGenome's technology portfolio will significantly bolster their long-read sequencing capabilities.
In January 2024, BD (Becton, Dickinson and Company) a leading global medical technology company, announced a collaboration agreement with Hamilton, a leading global manufacturer of laboratory automation technology, to develop automated applications together with robotics-compatible reagent kits to enable greater standardization and reduced human error when conducting large-scale single-cell multiomics experiments.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TABLE OF CONTENTS

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.2.1 INCLUSIONS & EXCLUSIONS

1.3 MARKET SCOPE

1.3.1 MARKETS COVERED

1.3.2 YEARS CONSIDERED FOR THE STUDY

1.4 CURRENCY

1.5 LIMITATIONS

1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA

2.1.1 SECONDARY DATA

2.1.2 PRIMARY DATA

2.2 MARKET SIZE ESTIMATION

2.2.1 INSIGHTS FROM PRIMARY

2.2.2 SEGMENT ASSESSMENT METHODOLOGY

2.3 MARKET GROWTH RATE PROJECTIONS

2.4 DATA TRIANGULATION

2.5 RESEARCH ASSUMPTIONS

2.6 LIMITATIONS

2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

5.2.1 DRIVERS

5.2.2 RESTRAINTS

5.2.3 OPPORTUNITIES

5.2.4 CHALLENGES

5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS BUSINESS

5.4 PRICING ANALYSIS

5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT

5.4.2 AVERAGE SELLING PRICE TREND, BY REGION

5.5 SUPPLY CHAIN ANALYSIS

5.6 VALUE CHAIN ANALYSIS

5.7 ECOSYSTEM ANALYSIS

5.8 IMPACT OF AI/GEN AI

5.9 TECHNOLOGY ANALYSIS

5.9.1 KEY TECHNOLOGIES

5.9.2 COMPLEMENTARY TECHNOLOGIES

5.9.3 ADJACENT TECHNOLOGIES

5.10 PATENT ANALYSIS

5.11 KEY CONFERENCES & EVENTS 2025-2026

5.12 REGULATORY LANDSCAPE

5.12.1 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS

5.12.2 REGULATORY FRAMEWORK

5.13 PORTER’S FIVE FORCES ANALYSIS

5.13.1 THREAT OF NEW ENTRANTS

5.13.2 THREAT OF SUBSTITUTE

5.13.3 BARGAINING POWER OF SUPPLIERS

5.13.4 BARGAINING POWER OF BUYERS

5.13.5 INTENSITY OF COMPETITION RIVALRY

5.14 KEY STAKEHOLDERS AND BUYING CRITERIA

5.14.1 KEY STAKEHOLDERS IN THE BUYING PROCESS

5.14.2 BUYING CRITERIA FOR END USERS

5.15 INVESTMENT AND FUNDING SCENARIO

6 SINGLE CELL MULTI-OMICS MARKET, BY PRODUCT & SERVICE

6.1 INTRODUCTION

6.2 PRODUCT

6.2.1 INSTRUMENTS/SYSTEMS & SOFTWARE

6.2.2 KITS & REAGENTS

6.2.3 OTHER CONSUMABLES

6.3 SERVICE

7 SINGLE CELL MULTI-OMICS MARKET, BY WORKFLOW

7.1 INTRODUCTION

7.2 SAMPLE PREPARATION

7.3 SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION

7.4 DATA VISUALIZATION & ANALYSIS

8 SINGLE CELL MULTI-OMICS MARKET, BY TECHNOLOGY

8.1 INTRODUCTION

8.2 GENOMICS

8.3 TRANSCRIPTOMICS

8.4 PROTEOMICS

8.5 OTHER TECHNOLOGIES (EPIGENOMICS, METABOLOMICS, SPATIAL ANALYSIS)

9 SINGLE CELL MULTI-OMICS MARKET, BY APPLICATION

9.1 INTRODUCTION

9.2 BASIC RESEARCH

9.3 TRANSLATIONAL RESEARCH

9.3.1 CANCER RESEARCH

9.3.2 IMMUNOLOGY RESEARCH

9.3.3 NEUROLOGY RESEARCH

9.3.4 STEM CELL RESEARCH

9.3.5 OTHER RESEARCH APPLICATIONS

9.4 CLINICAL DIAGNOSTICS

9.5 OTHER APPLICATIONS (IF ANY)

10 SINGLE CELL MULTI-OMICS MARKET, BY TECHNIQUE

10.1 INTRODUCTION

10.2 NEXT-GENERATION SEQUENCING (EXCLUDING NANOPORE SEQUENCING)

10.3 NANOPORE SEQUENCING

10.4 MASS SPECTROMETRY

10.5 OTHER TECHNIQUES (MASS CYTOMETRY, MICROFLUIDICS)

11 SINGLE CELL MULTI-OMICS MARKET, BY END USERS

11.1 INTRODUCTION

11.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES

11.3 ACADEMIC & RESEARCH INSTITUTES

11.4 HOSPITAL & DIAGNOSTIC LABORATORIES

11.5 OTHER END USERS (CELL BANKS, IVF CENTERS, CONTRACT RESEARCH ORGANIZATIONS)

12 SINGLE CELL MULTI-OMICS MARKET, BY REGION

12.1 INTRODUCTION

12.2 NORTH AMERICA

12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA

12.2.2 US

12.2.3 CANADA

12.3 EUROPE

12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE

12.3.2 GERMANY

12.3.3 FRANCE

12.3.4 UK

12.3.5 ITALY

12.3.6 SPAIN

12.3.7 REST OF EUROPE

12.4 ASIA PACIFIC

12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC

12.4.2 JAPAN

12.4.3 CHINA

12.4.4 INDIA

12.4.5 SOUTH KOREA

12.4.6 AUSTRALIA

12.4.7 REST OF ASIA PACIFIC

12.5 LATIN AMERICA

12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA

12.5.2 BRAZIL

12.5.3 REST OF LATIN AMERICA

12.6 MIDDLE EAST

12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST

12.6.2 GCC

12.6.2.1 SAUDI ARABIA (KSA)

12.6.2.2 UNITED ARAB EMIRATES (UAE)

12.6.2.3 REST OF GCC

12.6.3 REST OF MIDDLE EAST

12.7 AFRICA

12.7.1 MACROECONOMIC OUTLOOK FOR AFRICA

13 COMPETITIVE LANDSCAPE

13.1 INTRODUCTION

13.2 KEY PLAYERS STRATEGIES/ RIGHT TO WIN

13.3 REVENUE SHARE ANALYSIS (TOP 4-5 PLAYERS), 2019-2023

13.4 MARKET SHARE ANALYSIS (TOP 4-5 PLAYERS), 2023

13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023

13.5.1 STARS

13.5.2 EMERGING LEADERS

13.5.3 PERVASIVE PLAYERS

13.5.4 PARTICIPANTS

13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023

13.5.5.1 OVERALL COMPANY FOOTPRINT

13.5.5.2 PRODUCT FOOTPRINT

13.5.5.3 TECHNOLOGY FOOTPRINT

13.5.5.4 APPLICATION FOOTPRINT

13.5.5.5 REGION FOOTPRINT

13.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023

13.6.1 PROGRESSIVE COMPANIES

13.6.2 RESPONSIVE COMPANIES

13.6.3 DYNAMIC COMPANIES

13.6.4 STARTING BLOCKS

13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023

13.6.5.1 DETAILED LIST OF KEY STARTUPS/ SMES

13.6.5.2 COMPETITIVE BENCHMARKING OF KEY STARTUPS/ SMES

13.7 COMPETITIVE SCENARIO

13.7.1 DEALS

13.7.2 OTHER DEVELOPMENTS

13.8 BRAND/ PRODUCT COMPARATIVE ANALYSIS

13.9 VENDOR VALUATION AND FINANCIAL METRICS OF THE SINGLE CELL MULTI-OMICS MARKET

14 COMPANY PROFILES

14.1 KEY COMPANIES

14.1.1 10X GENOMICS

14.1.2 OXFORD NANOPORE TECHNOLOGIES PLC.

14.1.3 ILLUMINA, INC.

14.1.4 BD

14.1.5 MERCK KGAA

14.1.6 AGILENT TECHNOLOGIES, INC.

14.1.7 THERMO FISHER SCIENTIFIC

14.1.8 BRUKER

14.1.9 DANAHER CORPORATION

14.1.10 QIAGEN

14.1.11 PACBIO

14.1.12 BIO-TECHNE

14.1.13 STANDARD BIOTOOLS

14.1.14 BIO-RAD LABORATORIES, INC.

14.2 OTHER PLAYERS

Note: The provided list of players is tentative and subject to change during the research. Details on business overview, financial information (based on availability), product portfolio, and recent developments will be provided for 20-25 companies.

15 APPENDIX

15.1 DISCUSSION GUIDE

15.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL

15.3 AVAILABLE CUSTOMIZATIONS

15.4 RELATED REPORTS

15.5 AUTHOR DETAILS

Request for detailed methodology, assumptions & how numbers were triangulated.

Please share your problem/objectives in greater details so that our analyst can verify if they can solve your problem(s).

3 3 0 0 2

Manage preferences :

Select all
News-Letters with latest Market insights
Information & discussion on the relevant new products and services
Information & discussion on Market insights and Market information
Information & discussion on our events and conferences
Preferred modes for discussion
- Select all
- Email Phone Professional and social network (Linkedin, etc)

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.